Health economic assessment of Kymriah in diffuse large B-cell lymphoma


20 June 2019 - TLV has produced a health economic knowledge base for county councils for CAR-T cell treatment Kymriah (tisagenlecleucel) in the treatment of patients with diffuse large-cell B cell lymphoma. 

TLV assesses the severity of the disease as very high. Adult patients with diffuse large cell B cell lymphoma who have not responded to or relapsed after two or more treatment trials have a very poor prognosis.

The clinical effect of Kymriah is very uncertain. Trying to determine the relative effect of treatment with Kymriah on the basis of the current data implies an overly accurate estimate to constitute a guide when assessing the reasonable cost of the action.

Read TLV News (Swedish)

Michael Wonder

Posted by:

Michael Wonder